G. Hendriks¹, E. Adriaens², A. Allemang³, J. van Benthem⁴, J. Clements⁵, G. Cole⁶, M. Engel⁷, A. Hamel⁸, D. Kidd⁵, S. Kellum⁹, D. Kirkland¹⁰, T. Kiyota⁶, A. Myhre⁹, V. Naëssens¹¹, S. Pfuhler³, M. Roy⁸, R. Sattivari⁹, M. Schuler⁷, P. Vanparys¹², and A. Zeller¹¹. ¹Toxys, Leiden, Netherlands; ²Adriaens Consulting, Allter, Belgium; ³Procter & Gamble, Mason, OH; ⁴Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, Netherlands; ⁵Labcorp, Harrogate, United Kingdom; ⁶Genentech Inc., San Francisco, CA; ⁷Pfizer Inc., Groton, CT; ⁸Charles River Laboratories, Senneville, QC, Canada; ⁹Corteva Agriscience, Newark, DE; ¹⁰Kirkland Consulting, Tadcaster, United Kingdom; ¹¹Roche, Basel, Switzerland; and ¹²Consultant: Genetic Toxicology, Vosselaar, Belgium.